Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsIvo M. B. Francischetti, Robson de Queiroz Monteiro, Jose Marcos C. Ribeiro
Life of this patent
Estimating the term…
Abstract
The invention provides methods for treatment of tissue factor (TF) mediated or associated diseases or processes, such as cancer, by administering at least an active fragment of an Ixolaris polypeptide to a subject. The invention further includes identification of a subject in need of such treatment, and monitoring a subject for amelioration of at least one sign or symptom of the disease. The invention also features kits.
Claims21
A method of inhibiting growth of a cell expressing tissue factor (TF), comprising contacting the cell with an effective amount of an Ixolaris polypeptide such that the growth of the cell is inhibited, wherein the amount of Ixolaris polypeptide is 1-250 ug kg−1, wherein the Ixolaris polypeptide is at least 95% identical to SEQ ID NO:
- 2.
A method of treating a TF mediated or associated disease or process in a subject, comprising administering to the subject an Ixolaris polypeptide in an amount effective to treat the TF mediated or associated disease or process, wherein the amount of Ixolaris polypeptide is 1-250 ug kg−1, wherein the Ixolaris polypeptide is at least 95% identical to SEQ ID NO:
- 2.
A method of treating a tumor in a subject, comprising administering to the subject an Ixolaris polypeptide in an amount effective to treat the tumor, wherein the amount of Ixolaris polypeptide is 1-250 ug kg−1, wherein the Ixolaris polypeptide is at least 95% identical to SEQ ID NO:
- 2.
A method of treating cancer in a subject comprising administering to the subject an Ixolaris polypeptide in an amount effective to treat the cancer, wherein the amount of Ixolaris polypeptide is 1-250 ug kg−1, wherein the Ixolaris polypeptide is at least 95% identical to SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.